Exenatide vs Liraglutide
The two first-generation GLP-1 agonists — the incretin-mimic original vs the once-daily that followed — head to head across diabetes and weight outcomes. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.
Exenatide
ApprovedExenatide is a special medicine that acts like a natural hormone in your body called GLP-1. It is often used by people with type 2 diabetes to help control their blood sugar levels.
Liraglutide
ApprovedAlso: PF-07976016 and Liraglutide, Liraglutide and Exercise
Liraglutide is a medicine that acts like a natural hormone in the body. It is used by doctors to help people with type 2 diabetes control their blood sugar levels.
At a Glance
| Exenatide | Liraglutide | |
|---|---|---|
| Research status | Approved | Approved |
| Highest-tier evidence | Peer-reviewed study | Peer-reviewed study |
| Research citations | 23 | 21 |
| Dosing routes | SubQ | SubQ |
| Receptor targets | — | — |
| Half-life | — | — |
| Known side effects | 28 | 97 |
Research Areas
Top preclinical research areas — cited studies for each.
Exenatide
- Augmentation of hyperglycemia-induced insulin secretion
- Suppression of glucagon secretion
- Deceleration of gastric emptying
- Reduction in calorie intake and body weight
- Prevention of cardiovascular events (e.g., myocardial infarction, stroke)
Liraglutide
- Glycemic Control in Type 2 Diabetes
- Reduction in Waist Circumference
- Reduction in Visceral Adipose Tissue (VAT)
- Improvement of glycemic control in T2D via pancreatic GLP-1R activation
- Significant weight loss and reduced energy intake via brain GLP-1R action
How People Use It
Reported routines — research only, not medical advice.
Exenatide
- SubQ — Twice daily (b.i.d.)
- SubQ — 2 mg
- SubQ — Continuous subcutaneous infusion via osmotic mini-pump
- SubQ — Once weekly
- SubQ — Twice daily
- SubQ — Once weekly
- SubQ — Twice daily; mean terminal half-life 2.4 h
- SubQ — Once weekly
- SubQ — 2 mg once weekly
- SubQ — 0.8 mg and 2 mg doses
- SubQ — 0.8 and 2.0 mg, once weekly
Liraglutide
- SubQ — Once daily administration
- SubQ — Daily
- SubQ — Once-daily, dose adjusted individually
- SubQ — 3 mg once daily
- SubQ — 0.6 mg daily (Week 1), 1.2 mg daily (Standard), 1.8 mg daily (Max)
- SubQ — 3 mg daily
- SubQ — 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg
- SubQ — 0.6 mg, 1.2 mg, or 1.8 mg
- SubQ — Single subcutaneous injection
- SubQ — Single subcutaneous injection
- SubQ — Once daily
The Evidence
Key studies — click through to verify each on PubMed.
Exenatide
23 sourced studies
- Source
Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
2013 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Liraglutide
21 sourced studies
- Source
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
2020 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
2009 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Liraglutide and Renal Outcomes in Type 2 Diabetes.
2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Decision Guide
How to Choose
Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.
Source Exenatide
Shop ExenatideSource Liraglutide